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The majority of low-risk patients with clinically localized prostate cancer have a high likelihood of 
disease-free survival, regardless of the treatment option chosen1). In contrast, patients with high-risk 
prostate cancer with high Gleason score, elevated PSA level, and advanced clinical stage have a high 
probability of treatment failure after initial management by single-treatment modalities, such as 
radical prostatectomy (RP), external beam radiation therapy (EBRT), or brachytherapy2, 3). Therefore, 
it is extremely important to establish the most effective treatment strategy for patients with high-risk 
prostate cancer. As high-risk patients may have locally advanced disease with direct extension and/or 
micrometastases, various combinations of treatments have been developed to augment cancer-specific 
survival. Neoadjuvant and/or adjuvant androgen deprivation therapy (ADT) offer synergistic 
enhancement of RT or RP due to induction of apoptosis. Moreover, ADT may play a role in 
elimination of occult systemic disease4). Whereas many studies have demonstrated benefits of ADT 
used in conjunction with EBRT to treat locally advanced prostate cancer5, 6), questions and criticisms 
remain, including the details of the duration, timing, and contents of ADT. 
A recent report７) by  Denham et al.offered some insight into the above questions. 
The aim of the study (TROG 96.01 trial) was to assess whether 3-month or 6-month short-term 
neoadjuvant ADT could decrease clinical progression and mortality rate after radiotherapy (EBRT) 
for locally advanced prostate cancer. In this study, 818 men with T2b, T2c, T3, and T4 N0 M0 prostate 
cancer were randomly assigned to receive radiotherapy alone, 3 months of neoadjuvant ADT plus 
radiotherapy, or 6 months of neoadjuvant ADT plus radiotherapy. The radiotherapy dose for all groups 
was 66 Gy, delivered to the prostate and seminal vesicles (excluding pelvic nodes). Neoadjuvant ADT 
consisted of 3.6 mg of goserelin every month and 250 mg of flutamide given orally three times a day. 
Primary endpoints were prostate cancer-specific mortality and all-cause mortality. After a median 
follow-up of 10.6 years, 3 months of neoadjuvant ADT decreased the cumulative incidence of PSA 
progression (p=0.003) and local progression (p=0.0005), and improved event-free survival (p<0.0001) 
compared with radiotherapy alone. Six months of neoadjuvant ADT further reduced PSA progression 
(p<0.0001) and local progression (p=0.0001), and led to a greater improvement in event-free survival 
(p<0.0001) compared with radiotherapy alone. However, 3-month neoadjuvant ADT had no effect on 
distant progression (p=0.550), prostate cancer-specific mortality (p=0.398), or all-cause mortality 
(p=0.180) compared with radiotherapy alone. In contrast, 6-month neoadjuvant ADT decreased 
distant progression (p=0.001), prostate cancer-specific mortality (p=0.0008), and all-cause mortality 
(p=0.0008) compared with radiotherapy alone. Treatment-related morbidity was not increased with 
neoadjuvant ADT within the first 5 years after randomization. 
From the above results, it was concluded that 6 months of neoadjuvant ADT combined with 
radiotherapy is an effective treatment option for locally advanced prostate cancer, particularly in men 
without nodal metastases or preexisting metabolic comorbidities. 
As the prolonged use of ADT may result in an increase in adverse events, investigation of the 
optimal duration of neoadjuvant and/or adjuvant ADT with maximized outcome and minimized 
toxicity is a logical step in the management of localized high-risk prostate cancer. Although this trial 
showed that 3-month neoadjuvant use had no beneficial effects on distant progression, prostate 
cancer-specific mortality, or all-cause mortality compared with radiotherapy alone and that 6-month 
neoadjuvant ADT decreased distant progression, prostate cancer-specific mortality, and all-cause 
mortality compared with radiotherapy alone, further longer neoadjuvant ADT may produce better 
outcomes than 6 months of neoadjuvant ADT. Trials regarding adjuvant ADT have already 
demonstrated the superiority of longer periods of adjuvant ADT. Therefore, with sufficient care to 
prevent adverse effects due to ADT, better outcomes with further longer neoadjuvant ADT may be 
achieved. 
Trimodality treatment (EBRT + brachytherapy ± ADT) has attracted attention as another method 
to produce better outcomes for high-risk prostate cancer. According to the American Brachytherapy 
Society (ABS), brachytherapy alone is not recommended for high-risk PCa but can be used as a boost 
in conjunction with EBRT8). In this multimodal approach, the combined brachytherapy and EBRT 
theoretically delivers a possible escalated dose to the prostate and at the same time to extracapsular 
cancer extension. Although the ABS provides no clear indications for neoadjuvant and/or adjuvant 
ADT with combination of brachytherapy and EBRT in high-risk prostate cancer, the duration of ADT 
could be reduced with such multi-modality RT. According to NCCN Guidelines™ version 1, 2011, the 
trimodality treatment (EBRT + brachytherapy ± short-term ADT) is added as a recommended arm in 
cases of high- and very high-risk prostate cancer. 
In contrast to the many efforts to develop better treatments for RT with ADT, there have been few 
clinical trials investigating the effectiveness of neoadjuvant or adjuvant ADT with RP. One reason for 
this is that early studies of neoadjuvant ADT did not confirm the improvement of overall survival 
despite improvements in the pathological findings. Another reason is that surgeons may have less 
interest in medical treatments, such as ADT. However, surgeons should consider the best methods of 
improving the results in cases of high-risk prostate cancer, because recent reports have demonstrated 
the superiority of RT for high-risk prostate cancer compared with RP9). 
Finally, it should be stressed that it may be possible to eradicate high-risk or locally advanced prostate 
cancer with appropriate use of ADT in combination with RT or RP. Therefore, further well-designed 
clinical trials are required.  
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